{"id":41409,"date":"2025-09-15T16:28:38","date_gmt":"2025-09-15T08:28:38","guid":{"rendered":"https:\/\/flcube.com\/?p=41409"},"modified":"2025-09-15T16:28:39","modified_gmt":"2025-09-15T08:28:39","slug":"hitgen-and-bioage-launch-phase-i-study-of-bge%e2%80%91102-a-novel-nlrp3-inhibitor","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=41409","title":{"rendered":"HitGen and BioAge Launch Phase\u202fI Study of BGE\u2011102, a Novel NLRP3 Inhibitor"},"content":{"rendered":"\n<p>China\u2011based <strong>HitGen Inc. (<a href=\"https:\/\/www.google.com\/finance\/quote\/688222:SHA\">SHA: 688222<\/a>)<\/strong> announced that its partner, <strong>BioAge Labs, Inc. (<a href=\"https:\/\/www.google.com\/finance\/quote\/BIOA:NASDAQ\">NASDAQ: BIOA<\/a>)<\/strong>, has begun a <strong>Phase\u202fI clinical study<\/strong> of <strong>BGE\u2011102<\/strong>, a first\u2011in\u2011class oral small\u2011molecule NLRP3 inhibitor. The lead compound was identified through HitGen\u2019s proprietary <strong>DNA\u2011encoded library (DEL)<\/strong> platform, underscoring the value of high\u2011throughput screening in modern drug discovery.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-what-is-bge-102-and-why-it-matters\">What Is BGE\u2011102 and Why It Matters<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target:<\/strong> BGE\u2011102 inhibits the <strong>NLRP3 inflammasome<\/strong>, a key driver of chronic inflammation linked to obesity, type\u20112 diabetes, and cardiovascular disease.<\/li>\n\n\n\n<li><strong>Profile:<\/strong> The molecule boasts a <strong>novel chemical scaffold<\/strong>, high potency, and <strong>excellent brain permeability<\/strong>, positioning it as a promising candidate for central\u2011obesity therapeutics.<\/li>\n\n\n\n<li><strong>Clinical Milestone:<\/strong> The Phase\u202fI trial will evaluate safety, tolerability, pharmacokinetics, and preliminary efficacy in overweight and obese adults.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-partnership-highlights\">Partnership Highlights<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Discovery Synergy:<\/strong> In <strong>April\u202f2021<\/strong>, the two companies jointly announced the discovery of lead compounds from HitGen\u2019s DEL library, paving the way for BGE\u2011102\u2019s development.<\/li>\n\n\n\n<li><strong>Patent Collaboration:<\/strong> A <strong>joint patent application<\/strong> covering the DEL\u2011derived compounds was filed, reinforcing intellectual\u2011property protection.<\/li>\n\n\n\n<li><strong>Milestone Payments:<\/strong> While the exact figures remain undisclosed, HitGen is entitled to milestone payments under the collaboration agreement, reflecting the strategic importance of the partnership.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-forward-looking-statements\">Forward\u2011Looking Statements<\/h2>\n\n\n\n<p>HitGen and BioAge intend to expand the use of HitGen\u2019s DEL platform across additional therapeutic areas. The ongoing Phase\u202fI study of BGE\u2011102 is a critical step toward advancing a novel obesity therapy that could address unmet medical needs in a market projected to grow sharply over the next decade.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China\u2011based HitGen Inc. (SHA: 688222) announced that its partner, BioAge Labs, Inc. (NASDAQ: BIOA), has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":41412,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[290,1044,4351,1042],"class_list":["post-41409","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-bioage-labs","tag-hitgen","tag-nasdaq-bioa","tag-sha-688222"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>HitGen and BioAge Launch Phase\u202fI Study of BGE\u2011102, a Novel NLRP3 Inhibitor - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China\u2011based HitGen Inc. (SHA: 688222) announced that its partner, BioAge Labs, Inc. (NASDAQ: BIOA), has begun a Phase\u202fI clinical study of BGE\u2011102, a first\u2011in\u2011class oral small\u2011molecule NLRP3 inhibitor. The lead compound was identified through HitGen\u2019s proprietary DNA\u2011encoded library (DEL) platform, underscoring the value of high\u2011throughput screening in modern drug discovery.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=41409\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HitGen and BioAge Launch Phase\u202fI Study of BGE\u2011102, a Novel NLRP3 Inhibitor\" \/>\n<meta property=\"og:description\" content=\"China\u2011based HitGen Inc. (SHA: 688222) announced that its partner, BioAge Labs, Inc. (NASDAQ: BIOA), has begun a Phase\u202fI clinical study of BGE\u2011102, a first\u2011in\u2011class oral small\u2011molecule NLRP3 inhibitor. The lead compound was identified through HitGen\u2019s proprietary DNA\u2011encoded library (DEL) platform, underscoring the value of high\u2011throughput screening in modern drug discovery.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=41409\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-15T08:28:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-15T08:28:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1507.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41409#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41409\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"HitGen and BioAge Launch Phase\u202fI Study of BGE\u2011102, a Novel NLRP3 Inhibitor\",\"datePublished\":\"2025-09-15T08:28:38+00:00\",\"dateModified\":\"2025-09-15T08:28:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41409\"},\"wordCount\":268,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41409#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1507.webp\",\"keywords\":[\"BioAge Labs\",\"HitGen\",\"NASDAQ: BIOA\",\"SHA: 688222\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41409#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41409\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=41409\",\"name\":\"HitGen and BioAge Launch Phase\u202fI Study of BGE\u2011102, a Novel NLRP3 Inhibitor - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41409#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41409#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1507.webp\",\"datePublished\":\"2025-09-15T08:28:38+00:00\",\"dateModified\":\"2025-09-15T08:28:39+00:00\",\"description\":\"China\u2011based HitGen Inc. (SHA: 688222) announced that its partner, BioAge Labs, Inc. (NASDAQ: BIOA), has begun a Phase\u202fI clinical study of BGE\u2011102, a first\u2011in\u2011class oral small\u2011molecule NLRP3 inhibitor. The lead compound was identified through HitGen\u2019s proprietary DNA\u2011encoded library (DEL) platform, underscoring the value of high\u2011throughput screening in modern drug discovery.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41409#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41409\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41409#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1507.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1507.webp\",\"width\":1080,\"height\":608,\"caption\":\"HitGen and BioAge Launch Phase\u202fI Study of BGE\u2011102, a Novel NLRP3 Inhibitor\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41409#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HitGen and BioAge Launch Phase\u202fI Study of BGE\u2011102, a Novel NLRP3 Inhibitor\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"HitGen and BioAge Launch Phase\u202fI Study of BGE\u2011102, a Novel NLRP3 Inhibitor - Insight, China&#039;s Pharmaceutical Industry","description":"China\u2011based HitGen Inc. (SHA: 688222) announced that its partner, BioAge Labs, Inc. (NASDAQ: BIOA), has begun a Phase\u202fI clinical study of BGE\u2011102, a first\u2011in\u2011class oral small\u2011molecule NLRP3 inhibitor. The lead compound was identified through HitGen\u2019s proprietary DNA\u2011encoded library (DEL) platform, underscoring the value of high\u2011throughput screening in modern drug discovery.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=41409","og_locale":"en_US","og_type":"article","og_title":"HitGen and BioAge Launch Phase\u202fI Study of BGE\u2011102, a Novel NLRP3 Inhibitor","og_description":"China\u2011based HitGen Inc. (SHA: 688222) announced that its partner, BioAge Labs, Inc. (NASDAQ: BIOA), has begun a Phase\u202fI clinical study of BGE\u2011102, a first\u2011in\u2011class oral small\u2011molecule NLRP3 inhibitor. The lead compound was identified through HitGen\u2019s proprietary DNA\u2011encoded library (DEL) platform, underscoring the value of high\u2011throughput screening in modern drug discovery.","og_url":"https:\/\/flcube.com\/?p=41409","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-15T08:28:38+00:00","article_modified_time":"2025-09-15T08:28:39+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1507.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=41409#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=41409"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"HitGen and BioAge Launch Phase\u202fI Study of BGE\u2011102, a Novel NLRP3 Inhibitor","datePublished":"2025-09-15T08:28:38+00:00","dateModified":"2025-09-15T08:28:39+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=41409"},"wordCount":268,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=41409#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1507.webp","keywords":["BioAge Labs","HitGen","NASDAQ: BIOA","SHA: 688222"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=41409#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=41409","url":"https:\/\/flcube.com\/?p=41409","name":"HitGen and BioAge Launch Phase\u202fI Study of BGE\u2011102, a Novel NLRP3 Inhibitor - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=41409#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=41409#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1507.webp","datePublished":"2025-09-15T08:28:38+00:00","dateModified":"2025-09-15T08:28:39+00:00","description":"China\u2011based HitGen Inc. (SHA: 688222) announced that its partner, BioAge Labs, Inc. (NASDAQ: BIOA), has begun a Phase\u202fI clinical study of BGE\u2011102, a first\u2011in\u2011class oral small\u2011molecule NLRP3 inhibitor. The lead compound was identified through HitGen\u2019s proprietary DNA\u2011encoded library (DEL) platform, underscoring the value of high\u2011throughput screening in modern drug discovery.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=41409#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=41409"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=41409#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1507.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1507.webp","width":1080,"height":608,"caption":"HitGen and BioAge Launch Phase\u202fI Study of BGE\u2011102, a Novel NLRP3 Inhibitor"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=41409#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"HitGen and BioAge Launch Phase\u202fI Study of BGE\u2011102, a Novel NLRP3 Inhibitor"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1507.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41409","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=41409"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41409\/revisions"}],"predecessor-version":[{"id":41413,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41409\/revisions\/41413"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/41412"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=41409"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=41409"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=41409"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}